-
Je něco špatně v tomto záznamu ?
Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum
Melichar B, Hyspler R, Dragounová E, Dvorák J, Kalábová H, Tichá A
Jazyk angličtina Země Velká Británie
NLK
BioMedCentral
od 2001-01-12
BioMedCentral Open Access
od 2001
Directory of Open Access Journals
od 2001
Free Medical Journals
od 2001
PubMed Central
od 2001
Europe PubMed Central
od 2001
Open Access Digital Library
od 2001-01-01
Open Access Digital Library
od 2001-01-01
Open Access Digital Library
od 2001-01-01
Medline Complete (EBSCOhost)
od 2001-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2001
Springer Nature OA/Free Journals
od 2001-12-01
PubMed
17688683
DOI
10.1186/1471-2407-7-155
Knihovny.cz E-zdroje
- MeSH
- adenokarcinom farmakoterapie metabolismus patologie MeSH
- cisplatina aplikace a dávkování MeSH
- dospělí MeSH
- financování organizované MeSH
- gastrointestinální trakt metabolismus MeSH
- intestinální absorpce účinky léků MeSH
- karboplatina aplikace a dávkování MeSH
- laktulosa metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- mannitol metabolismus MeSH
- monoklonální protilátky aplikace a dávkování MeSH
- nádory glandulární a epitelové farmakoterapie metabolismus patologie MeSH
- nádory prsu farmakoterapie metabolismus patologie MeSH
- nádory vaječníků farmakoterapie metabolismus patologie MeSH
- paclitaxel aplikace a dávkování MeSH
- permeabilita buněčné membrány účinky léků MeSH
- protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
- sacharasa metabolismus MeSH
- senioři MeSH
- xylosa metabolismus MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- ženské pohlaví MeSH
BACKGROUND: Combination of platinum derivatives with paclitaxel is currently the standard front line regimen for patients with epithelial ovarian carcinoma, and represents also an active regimen in patients with metastatic breast or unknown primary carcinomas. Measurement of intestinal permeability represents one of the potential methods of noninvasive laboratory assessment of gastrointestinal mucositis induced by chemotherapy, but little is known about intestinal permeability in patients treated with paclitaxel or platinum. METHODS: Intestinal permeability was assessed in 36 breast and ovarian cancer patients treated with paclitaxel/platinum combination by measuring, using capillary gas chromatography, urinary sucrose, lactulose, xylose and mannitol after oral challenge. The significance of differences during the therapy compared to pre-treatment values was studied by Wilcoxon paired test. The differences between groups of patient were studied by Mann-Whitney U test. Fisher exact test was used to compare the frequency in different subgroups. RESULTS: After administration of the first dose, a significant (p < 0.05) decrease in xylose absorption and increased lactulose/mannitol, sucrose/mannitol, lactulose/xylose and sucrose/xylose ratios were observed, but these parameters returned subsequently to pre-treatment levels. Patients who experienced serious (grade 3 or 4) toxicity had at baseline significantly lower percentages of xylose, mannitol and sucrose, and higher lactulose/mannitol ratio. Nine of 13 (69%) patients with baseline lactulose/mannitol ratio 0.070 or above experienced serious toxicity compared to 4 out of 23 patients (17%) with the ratio below 0.070 (p = 0.002). Post-treatment lactulose, lactulose/mannitol, sucrose/mannitol and lactulose/xylose ratios were significantly increased in patients with serious toxicity. CONCLUSION: A transient significant increase in lactulose/monosaccharide and sucrose/monosaccharide ratios was observed in ovarian and breast cancer patients treated with paclitaxel and platinum. Increased lactulose absorption, lactulose/mannitol, sucrose/mannitol and lactulose/xylose ratios were evident in patients with grade 3 or 4 toxicity, and increased baseline lactulose/mannitol ratio predicted serious toxicity.
Citace poskytuje Crossref.org
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10001000
- 003
- CZ-PrNML
- 005
- 20111210154841.0
- 008
- 100117s2007 xxk e eng||
- 009
- AR
- 024 __
- $a 10.1186/1471-2407-7-155 $2 doi
- 035 __
- $a (PubMed)17688683
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Melichar, Bohuslav, $d 1965- $7 skuk0000853
- 245 10
- $a Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum / $c Melichar B, Hyspler R, Dragounová E, Dvorák J, Kalábová H, Tichá A
- 314 __
- $a Department of Oncology & Radiotherapy, Charles University Medical School & Teaching Hospital, Sokolská 581, Building 23, 500 05, Hradec Králové, Czech Republic. melichar@fnhk.cz
- 520 9_
- $a BACKGROUND: Combination of platinum derivatives with paclitaxel is currently the standard front line regimen for patients with epithelial ovarian carcinoma, and represents also an active regimen in patients with metastatic breast or unknown primary carcinomas. Measurement of intestinal permeability represents one of the potential methods of noninvasive laboratory assessment of gastrointestinal mucositis induced by chemotherapy, but little is known about intestinal permeability in patients treated with paclitaxel or platinum. METHODS: Intestinal permeability was assessed in 36 breast and ovarian cancer patients treated with paclitaxel/platinum combination by measuring, using capillary gas chromatography, urinary sucrose, lactulose, xylose and mannitol after oral challenge. The significance of differences during the therapy compared to pre-treatment values was studied by Wilcoxon paired test. The differences between groups of patient were studied by Mann-Whitney U test. Fisher exact test was used to compare the frequency in different subgroups. RESULTS: After administration of the first dose, a significant (p < 0.05) decrease in xylose absorption and increased lactulose/mannitol, sucrose/mannitol, lactulose/xylose and sucrose/xylose ratios were observed, but these parameters returned subsequently to pre-treatment levels. Patients who experienced serious (grade 3 or 4) toxicity had at baseline significantly lower percentages of xylose, mannitol and sucrose, and higher lactulose/mannitol ratio. Nine of 13 (69%) patients with baseline lactulose/mannitol ratio 0.070 or above experienced serious toxicity compared to 4 out of 23 patients (17%) with the ratio below 0.070 (p = 0.002). Post-treatment lactulose, lactulose/mannitol, sucrose/mannitol and lactulose/xylose ratios were significantly increased in patients with serious toxicity. CONCLUSION: A transient significant increase in lactulose/monosaccharide and sucrose/monosaccharide ratios was observed in ovarian and breast cancer patients treated with paclitaxel and platinum. Increased lactulose absorption, lactulose/mannitol, sucrose/mannitol and lactulose/xylose ratios were evident in patients with grade 3 or 4 toxicity, and increased baseline lactulose/mannitol ratio predicted serious toxicity.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a adenokarcinom $x farmakoterapie $x metabolismus $x patologie $7 D000230
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a monoklonální protilátky $x aplikace a dávkování $7 D000911
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a nádory prsu $x farmakoterapie $x metabolismus $x patologie $7 D001943
- 650 _2
- $a karboplatina $x aplikace a dávkování $7 D016190
- 650 _2
- $a permeabilita buněčné membrány $x účinky léků $7 D002463
- 650 _2
- $a cisplatina $x aplikace a dávkování $7 D002945
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a gastrointestinální trakt $x metabolismus $7 D041981
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a intestinální absorpce $x účinky léků $7 D007408
- 650 _2
- $a laktulosa $x metabolismus $7 D007792
- 650 _2
- $a mannitol $x metabolismus $7 D008353
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a nádory glandulární a epitelové $x farmakoterapie $x metabolismus $x patologie $7 D009375
- 650 _2
- $a nádory vaječníků $x farmakoterapie $x metabolismus $x patologie $7 D010051
- 650 _2
- $a paclitaxel $x aplikace a dávkování $7 D017239
- 650 _2
- $a sacharasa $x metabolismus $7 D013393
- 650 _2
- $a xylosa $x metabolismus $7 D014994
- 700 1_
- $a Hyšpler, Radomír, $d 1972- $7 nlk20040155091
- 700 1_
- $a Dragounová, Emanuela $7 xx0081952
- 700 1_
- $a Dvořák, Josef, $d 1966- $7 xx0072583
- 700 1_
- $a Kalábová, Hana. $7 xx0240731
- 700 1_
- $a Tichá, Alena, $d 1976- $7 xx0076494
- 773 0_
- $w MED00008171 $t BMC cancer $g č. 7 (2007), s. 155 $x 1471-2407
- 910 __
- $a ABA008 $b x $y 8
- 990 __
- $a 20100114083259 $b ABA008
- 991 __
- $a 20100215120121 $b ABA008
- 999 __
- $a ok $b bmc $g 703728 $s 566170
- BAS __
- $a 3
- BMC __
- $a 2007 $c 7 $d 155 $i 1471-2407 $m BMC cancer $x MED00008171
- LZP __
- $a 2010-b1/vtme